Press Releases

 
Press Releases
Date Title and Summary View
Oct 10, 2017 MADISON, Wis. and CASTRES, France, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), together with leading French pharmaceutical company Pierre Fabre, today announce the extension of their ongoing collaboration to develop new...
PDF
Sep 29, 2017 MADISON, Wis., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will present and meet with investors at The MicroCap Conference on Thursday, October 5th at 12:30 PM ET at The Esse...
PDF
Sep 27, 2017 MADISON, Wis., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that a patient treated with the company's lead PDC™ compound, CLR 131 in the fourth cohort of its Phase I dose escalation safety trial in re...
PDF
Sep 21, 2017 MADISON, Wis., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), and Onconova Therapeutics (Nasdaq:ONTX) today announced that they have entered into a strategic collaboration to develop new phospholipid drug conjugates (PDCs) c...
PDF
Sep 20, 2017 MADISON, Wis., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), today announced that president and CEO Jim Caruso will present and meet with investors at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26th at 9:30 A...
PDF
Sep 18, 2017 MADISON, Wis., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), announced that effective today Jarrod Longcor, the company's senior vice president of corporate development and operations, has been promoted to chief business officer.  In his n...
PDF
Sep 6, 2017 MADISON, Wis., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused biotechnology company (the "company"), today announced that it will present and meet with investors at the 19th Annual Rodman and Renshaw Global Investment Conference on Tuesday, September 12th a...
PDF
Aug 22, 2017 MADISON, Wis., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that show significant improved pharmacologic activity ve...
PDF
Aug 14, 2017 MADISON, Wis., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces financial results for the second quarter of 2017.  Management will host a teleconference and live webcast to review these results, including a revi...
PDF
Aug 8, 2017 MADISON, Wis., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces its lead PDC compound, CLR 131 has achieved a median overall survival of 22.5 months to date after a single dose infusion of 12.5mCi/m2 ...
PDF
Page: FirstPrevious
2
... NextLast